NCT06963281View on ClinicalTrials.gov

Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

285

Participants

Timeline

Start Date

April 29, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

March 31, 2028

Conditions
Solid Tumors
Interventions
DRUG

IBI3020

Recombinant anti-CEACAM5 monoclonal antibody - dual-payload conjugate for injection

Trial Locations (9)

10461

RECRUITING

Montefiore Cancer Center, New York

32224

RECRUITING

Mayo Clinic - Florida, Jacksonville

55905

RECRUITING

Mayo Clinic - Rochester, Rochester

75039

RECRUITING

NEXT Dallas, Irving

77054

RECRUITING

NEXT Houston, Houston

85054

RECRUITING

Mayo Clinic - Arizona, Pheonix

Unknown

RECRUITING

The sixth affiliated hospital, Sun Yat-sen University, Guangzhou

RECRUITING

Shandong Cancer Hospital, Jinan

RECRUITING

Shanxi Cancer Hospital, Taiyuan

All Listed Sponsors
collaborator

Fortvita Biologics (USA)Inc.

INDUSTRY

lead

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

INDUSTRY